- Home
- PRQR vs GEVO Comparison
PRQR vs GEVO Comparison
Compare PRQR & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- GEVO
- Stock Information
- Founded
- PRQR 2012
- GEVO 2005
- Country
- PRQR Netherlands
- GEVO United States
- Employees
- PRQR N/A
- GEVO N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- PRQR Health Care
- GEVO Industrials
- Exchange
- PRQR Nasdaq
- GEVO Nasdaq
- Market Cap
- PRQR 179.1M
- GEVO 246.8M
- IPO Year
- PRQR 2014
- GEVO 2011
- Fundamental
- Price
- PRQR $2.18
- GEVO $1.51
- Analyst Decision
- PRQR Strong Buy
- GEVO Buy
- Analyst Count
- PRQR 8
- GEVO 2
- Target Price
- PRQR $8.88
- GEVO $7.58
- AVG Volume (30 Days)
- PRQR 371.0K
- GEVO 5.2M
- Earning Date
- PRQR 08-07-2025
- GEVO 08-07-2025
- Dividend Yield
- PRQR N/A
- GEVO N/A
- EPS Growth
- PRQR N/A
- GEVO N/A
- EPS
- PRQR N/A
- GEVO N/A
- Revenue
- PRQR $21,212,711.00
- GEVO $42,034,000.00
- Revenue This Year
- PRQR N/A
- GEVO $1,022.79
- Revenue Next Year
- PRQR N/A
- GEVO $12.26
- P/E Ratio
- PRQR N/A
- GEVO N/A
- Revenue Growth
- PRQR 85.91
- GEVO 145.38
- 52 Week Low
- PRQR $1.07
- GEVO $0.48
- 52 Week High
- PRQR $4.62
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- PRQR 65.20
- GEVO 65.52
- Support Level
- PRQR $1.89
- GEVO $1.17
- Resistance Level
- PRQR $2.54
- GEVO $1.39
- Average True Range (ATR)
- PRQR 0.13
- GEVO 0.10
- MACD
- PRQR 0.01
- GEVO 0.02
- Stochastic Oscillator
- PRQR 39.85
- GEVO 100.00
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.